HRT Financial’s MoonLake Immunotherapeutics MLTX Stock Holding History

HRT Financial’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.09M	Sell	487,583 -148,318	-23%	-$2.46M	0.02%	663
2025 Q4	$8.38M	Buy	635,901 +492,626	+344%	+$5.81M	0.03%	526
2025 Q3	$1.03M	Buy	+143,275	New	+$7.47M	﹤0.01%	1505
2024 Q4	–	Sell	-13,592	Closed	-$685K	–	2924
2024 Q3	$685K	Buy	+13,592	New	+$637K	﹤0.01%	1439
2024 Q2	–	Sell	-31,941	Closed	-$1.6M	–	2749
2024 Q1	$1.6M	Buy	31,941 +16,650	+109%	+$903K	0.01%	672
2023 Q4	$923K	Buy	+15,291	New	+$788K	0.01%	1031
2022 Q1	–	Sell	-14,258	Closed	-$141K	–	3558
2021 Q4	$141K	Buy	14,258 +7	+0%	+$70	﹤0.01%	2666
2021 Q3	$140K	Sell	14,251 -7	-0%	-$70	﹤0.01%	2801
2021 Q2	$147K	Hold	14,258	–	–	﹤0.01%	2496
2021 Q1	$146K	Hold	14,258	–	–	﹤0.01%	2388
2020 Q4	$154K	Buy	+14,258	New	+$151K	﹤0.01%	1565

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HRT Financial's MLTX Position: Q1 2026 in Review

HRT Financial reduced its MoonLake Immunotherapeutics (MLTX) stake by 23% in Q1 2026, selling an estimated $2.46M and leaving 487,583 shares worth $9.09M. The position accounts for 0.02% of the portfolio, ranked #663.

HRT Financial first reported a position in MLTX in Q4 2020 and has held it in 11 quarters since. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

HRT Financial held 487,583 shares of MoonLake Immunotherapeutics worth $9.09M as of Q1 2026.
HRT Financial sold 148,318 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $2.46M.
MoonLake Immunotherapeutics made up 0.02% of HRT Financial's portfolio in Q1 2026, its #663 holding.
HRT Financial first reported a position in MoonLake Immunotherapeutics in Q4 2020 and has held it in 11 quarters since.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on HRT Financial's 13F filing for Q1 2026, filed 14 May 2026.